Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic

Basit Öğe Kaydı
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorJuarez, Gema Maria Fernandez
dc.contributor.authorFloege, Juergen
dc.contributor.authorGoumenos, Dimitrios
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorvan Kooten, Cees
dc.date.accessioned2024-02-23T14:21:01Z
dc.date.available2024-02-23T14:21:01Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractThe coronavirus disease 2019 (COVID-19) pandemic has created major challenges for all countries around the globe. Retrospective studies have identified hypertension, cardiovascular disease, diabetes and older age as risk factors for high morbidity and mortality from COVID-19. There is a general concern that patients with immune-mediated kidney diseases, namely those on immunosuppressive therapies and/or those with more advanced kidney failure, could particularly be at risk for adverse outcomes due to a compromised antiviral immunity. Uncertainties exist on how management routines should be reorganized to minimize the risk of severe acute respiratory syndrome coronavirus 2 infection and what measures are necessary for infected patients. The aim of the present review of the Immunonephrology Working Group of the European Renal Association-European Dialysis and Transplant Association is to provide recommendations for the management of patients with immune-mediated kidney diseases based on the available evidence, similar circumstances with other infectious organisms and expert opinions from across Europe. Such recommendations may help to minimize the risk of encountering COVID-19 or developing complications during COVID-19 in patients with immune-mediated kidney disease.en_US
dc.description.sponsorshipDeutsche Forschungsgemeinschaft [AN372/24-1]en_US
dc.description.sponsorshipThe Immunonephrology Working Group receives financial and logistic support from ERA-EDTA. H.-J.A. was supported by the Deutsche Forschungsgemeinschaft (AN372/24-1).en_US
dc.identifier.doi10.1093/ndt/gfaa112
dc.identifier.endpage925en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue6en_US
dc.identifier.pmid32445573en_US
dc.identifier.scopus2-s2.0-85086346128en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage920en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfaa112
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13413
dc.identifier.volume35en_US
dc.identifier.wosWOS:000544176600006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19en_US
dc.subjectGlomerulonephritisen_US
dc.subjectLupusen_US
dc.subjectRenal Vasculitisen_US
dc.subjectSteroidsen_US
dc.titleRecommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemicen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu